ArticleImmunoHorizons2018
CD160 Stimulates CD8
Article in ImmunoHorizons, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 33 citations in OpenAlex.
- Proteomic Insights Into Human Induced Regulatory T Cells: The Role of LPXN and CD160 in Immune Suppression.Molecular & cellular proteomics : MCP · 2026Article
- CD160Cellular & molecular immunology · 2026Article
- Serotonin receptor 5-HTJournal for immunotherapy of cancer · 2025Article
- SPP1 + macrophages cause exhaustion of tumor-specific T cells in liver metastases.Nature communications · 2025Article
- The inactivated and ISA 61 VG adjuvanted vaccine enhances protection against cross-serotype Listeria monocytogenes.Veterinary research · 2025Article
- Ligands for Intestinal Intraepithelial T Lymphocytes in Health and Disease.Pathogens (Basel, Switzerland) · 2025Review
- Heterogeneity of CD8αα intraepithelial lymphocytes is transcriptionally conserved between TCRαβ and TCRγδ cell lineages.Frontiers in immunology · 2025Article
- A Paradoxical Tumor Antigen Specific Response in the Liver.bioRxiv : the preprint server for biology · 2024Article
- Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications.Breast cancer research : BCR · 2024Article
- Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling.Immunity · 2022Article
- Epithelial HVEM maintains intraepithelial T cell survival and contributes to host protection.Science immunology · 2022Article
- PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma.Scientific reports · 2022Article
- CD160 receptor in CLL: Current state and future avenues.Frontiers in immunology · 2022Review
- HVEM structures and mutants reveal distinct functions of binding to LIGHT and BTLA/CD160.The Journal of experimental medicine · 2021Article
- Article
- Expanded antigen-experienced CD160Journal for immunotherapy of cancer · 2021Article
- Functional Analysis of Immune Signature Genes in Th1* Memory Cells Links ISOC1 and Pyrimidine Metabolism to IFN-γ and IL-17 Production.Journal of immunology (Baltimore, Md. : 1950) · 2021Article
- Roles of BTLA in Immunity and Immune Disorders.Frontiers in immunology · 2021Review
- Mechanisms of activation of innate-like intraepithelial T lymphocytes.Mucosal immunology · 2020Review
- A Cross-Protective Vaccine Against 4b and 1/2bFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
CD160 promotes NK cell cytotoxicity and IFN-γ production, but the function of CD160 on CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.